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Hepatocellular carcinoma (HCC) often results from chronic liver injury and severe fibrosis or cirrhosis, but the
underlying molecular pathogenesis is unclear. We previously reported that deletion of glucose regulated protein 94
(GRP94), a major endoplasmic reticulum chaperone, in the bone marrow and liver leads to progenitor/stem cell
expansion. Since liver progenitor cell (LPC) proliferation can contribute to liver tumor formation, herewe examined the
effect of GRP94 deficiency on spontaneous liver tumorigenesis. Utilizing liver-specific Grp94 knockout mice driven by
Albumin-Cre (cGrp94f/f), we discovered that while wild-type livers are tumor free up to 24 months, cGrp94f/f livers
showed abnormal small nodules at 15months and developed HCC and ductular reactions (DRs) by 21months of age,
associating with increased liver injury, apoptosis and fibrosis. cGrp94f/f livers were progressively repopulated by
GRP94-positive hepatocytes. At 15 months, we observed expansion of LPCs and mild DRs, as well as increase in cell
proliferation. In examining the underlying mechanisms for HCC development in cGrp94f/f livers, we detected increase
in TGF-β1, activationofSMAD2/3, ERK, and JNK, and cyclinD1upregulation at the premalignant stage.While epithelial-
mesenchymal transition (EMT) was not evident, E-cadherin expression was elevated. Correlating with the recurrence
of GRP94 positive-hepatocytes, the HCC was found to be GRP94-positive, whereas the expanded LPCs and DRs
remained GRP94-negative. Collectively, this study uncovers that GRP94 deficiency in the liver led to injury, LPC
expansion, increased proliferation, activation of oncogenic signaling, progressive repopulation of GRP94-positive
hepatocytes and HCC development in aged mice.
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Glucose-regulated protein (GRP94), encoded in humans by
HSP90β1, shares 50% amino acid homolog with the heat shock
protein HSP90 [1,2]. It is an essential endoplasmic reticulum (ER)
chaperone, assisting in protein folding, processing and secretion of
selective clients. As such, GRP94 uniquely controls specific pathways
critical for cell adhesion, proliferation, and organ homeostasis [3–5].
GRP94 also maintains Ca2+ homeostasis in the ER and protects
cancer cells from apoptosis [6]. GRP94 can translocate to the cell
surface serving additional functions, including modulating immune
responses [2]. Recently, GRP94 has been implicated in tumorigenesis
with differential outcomes in a context dependent manner [2,7–9].
Thus, it is important to study the role of GRP94 in additional cancer
models and how it affects oncogenic signaling in vivo.
618 GRP94 as a Regulator of Liver Cancer in Aged Mice Chen et al. Neoplasia Vol. 16, No. 8, 2014Liver cancer is the fifth most common cancer worldwide, among
which hepatocellular carcinoma (HCC) accounts for 70-85% of total
cancer burden [10]. Late diagnosis, recurrence, and metastasis result
in a poor prognosis of HCC, and the 5-year survival rate of patients
undergoing surgical treatment is low [11]. HCC often occurs in
steatohepatitis or cirrhosis background [11,12] but the molecular
pathogenesis of cancer development remains elusive. Thus, it is
important to understand liver tumorigenic mechanisms so that new
treatments can be developed.
Liver regeneration is normally carried out by hepatocytes and
cholangiocytes (bile duct cells). However, during chronic liver injury
and cirrhosis, the dividing ability of these parenchymal cells is
compromised and activation of liver progenitor cells (LPCs) is
observed [12]. Due to its bi-potential, LPCs residing in the niche,
located in the most peripheral branches of the biliary tree, can
differentiate into hepatocytes and cholangiocytes to restore the liver
function [12]. Recently, the concept that liver cancer originates from
liver tumor-initiating cells (TICs), which can be derived from normal
LPCs, received much attention. Liver cancer with LPC characteristics
is particularly aggressive [13] and deregulated LPCs have been shown
to obtain tumor-initiating ability in vivo [14,15], suggesting that
LPCs might be the origin of at least part of liver cancer. Perturbation
of oncogenic signaling is central to tumorigenesis through their effects
on proliferation, apoptosis, and invasion. For example, human HCC
overexpresses TGF-β [16], which has been shown to transform LPCs
to TICs [17]. Other kinases reported to be upregulated in HCC
include JNK, AKT and ERK, with the latter associated with increased
proliferation of LPCs [18–21].
We previously identified GRP94 as a novel regulator of cell adhesion,
LPCs, and liver tumorigenesis [7]. By using Albumin-Cre (Alb-Cre)
system, we generated the liver-specific Grp94 knockout mouse model
(Grp94f/f; Alb-Cre or cGrp94f/f), and found GRP94 deficiency leads to
hyperproliferation of LPCs with minor liver injury, correlating with
impaired cell adhesion. Deletion of both Grp94 and Pten in the liver
(cPtenf/fGrp94f/f) accelerates HCC and cholangiocarcinoma (CC)
development, and selectively activates ERK. Since expanded LPCs
might become TICs, it is interesting to determine whether GRP94
ablation alone is sufficient to induce spontaneous liver tumors. This
study revealed liver injury and HCC formation in aged cGrp94f/f mice
with progressive repopulation of GRP94-positive hepatocytes,
upregulation of TGF-β1 concurrent with LPC expansion, as well
as activation of SMAD2/3, ERK, and JNK prior to the onset of liver
fibrosis and tumors. This study expands our knowledge of the biological
functions of GRP94 in liver homeostasis and cancer progression.Materials and Methods
Mice
Grp94f/f; Alb-Cre mice on a mixed C57BL/6; 129/Sv; 6xDBA2;
129 background were generated and genotyping was performed as
previously described [7]. Littermates lacking Alb-Cre served as WT
controls. Blood samples were collected through retro-orbital bleeding.
All protocols for animal use were reviewed and approved by the USC
Institutional Animal Care and Use Committee.
Histology and Immunostaining
Mouse liver tissues were fixed in 10% zinc formalin, embedded in
paraffin, sectioned at 4 μm, and subjected to H&E staining and
immunostaining as described [22]. Monoclonal rat anti-GRP94 (1:200)is from Enzo Life Sciences (Farmingdale, NY). Cell proliferation was
evaluated by Ki67 staining (SP-6, 1:50, Thermo Scientific, Waltham,
MA). Monoclonal mouse anti-glutamine synthetase (GS) (1:400, BD
Biosciences, San Jose, CA) was used to examine liver zonation.
Monoclonal mouse anti-hepatocyte paraffin 1 (HepPar1) (1:25,
DakoCytomation, Denmark A/S) and polyclonal rabbit anti-wide
spectrum cytokeratin (panCK) (1:75, Abcam, Cambridge, MA)
antibodies were used to identify hepatocytes and cholangiocytes/LPCs,
respectively. Mesenchymal cells were detected by monoclonal
mouse anti-α-SMA (1:2000, Sigma, St. Louis, MO). Monoclonal
rat anti-CD34 (1:100) is from BioLegend (San Diego, CA).
Plasma Biochemistry
Plasma alanine aminotransferase (ALT) was determined using ALT
Reagent (Raichem, San Diego, CA). Plasma alkaline phosphatase
(ALP) was measured following manufacturer’s instruction (Thermo
Scientific, Waltham, MA).
TUNEL Assay
Apoptosis was determined using TUNEL staining (Roche
Diagnostics, Mannheim, Germany).
Western Blot Analysis
Harvested tissues were frozen immediately, and homogenized in
RIPA buffer with added protease and phosphatase inhibitor cocktail
(Thermo Scientific, Waltham, MA). Cell lysates (25–30 μg) were
subjected to SDS-PAGE and Western blot analysis as described [22].
The primary antibodies used are as follows. Monoclonal rat anti-
GRP94 (1:5000) is fromEnzo Life Sciences (Farmingdale, NY). Rabbit
anti-ERK1/2 (1:1000), mouse anti-p-ERK1/2 (Thr202/Tyr204, E10,
1:1000), rabbit anti-AKT (1:1000), and rabbit anti-p-AKT (Ser473,
1:1000) are from Cell Signaling (Danvers, MA). Goat anti-SMAD2/3
(N-19, 1:1000), goat anti-p-SMAD2/3 (Ser423/425, 1:1000), rabbit
anti-JNK (FL, 1:1000), mouse anti-p-JNK (Thr183/Tyr185, G7,
1:1000), and rabbit anti-β-catenin (H-102, 1:1000) are from Santa
Cruz Biotechnology (Dallas, TX). Monoclonal rabbit anti-Cyclin D1
(SP4, 1:1000) is from Thermo Scientific (Waltham, MA). Monoclonal
mouse anti-E-cadherin (1:1000) is fromBDBiosciences (San Jose, CA).
Monoclonal rabbit anti-integrin β1 (clone EP1041Y, 1:1000) and
monoclonal mouse anti-active-β-catenin (anti-ABC) (clone 8E7,
1:1000) are from Millipore (Billerica, MA). Monoclonal rabbit anti-
vimentin (clone EPR3776, 1:1000) is from Epitomics (Burlingame,
CA). Mouse anti-β-actin (1:5000) is from Sigma (St. Louis, MO).
Fluorescent Microscopy
Immunofluorescence was visualized by Zeiss LSM 510 confocal
microscope equipped with LSM 510 Version 4.2 SP1 acquisition
software (Carl Zeiss). Confocal images were obtained with 40X oil
lens. Images were then processed with LSM Image Browser R4.2 and
Adobe Photoshop CS5.
Statistical Analysis
Statistical significance was assayed by 2-tailed Student’s t test, and
the error bars reflect standard error (s.e.).
Results
Spontaneous Liver Tumor Development in Aged cGrp94f/f Mice
In following the effect of long-term GRP94 deficiency on the
mouse liver, we observed that while wild-type (WT) livers were
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Alb-Cre mice (referred to as cGrp94f/f) developed small nodules at
15 months and prominent liver tumors by 21 months (Figure 1A
and B). As noted previously [7], the cGrp94f/f liver weight relative to
the whole body of mice at 2 and 9 months were lower than the WT.Figure 1. Spontaneous liver tumor formation in aged cGrp94f/f mice.
solid and open circles represent mice with and without tumors, respe
and 21 months. Black arrowheads indicate small nodules (SN). The ins
the liver surface. (C) Liver weight to body weight percentage in W
measurements. (E) Quantitation of TUNEL-positive cells in cGrp94f/f live
and ***P b 0.001).However, consistent with tumor development, this decrease was
lower at 15 months and by 21 months, cGrp94f/f livers were 1.6-fold
higher than the WT (Figure 1C). To examine liver injury in cGrp94f/f
mice, we measured levels of plasma alanine aminotransferase (ALT)
and alkaline phosphatase (ALP). While there was no increase in these(A) Liver tumor spectrum. Each circle represents one mouse. The
ctively (***P b 0.001, χ2 test). (B) Representative liver pictures at 15
et shows the enlarged SN. White arrowheads denote tumors (T) on
T and cGrp94f/f mice at indicated ages. (D) Plasma ALT and ALP
rs at indicated ages. All data are presented asmean± s.e. (*P b 0.05
620 GRP94 as a Regulator of Liver Cancer in Aged Mice Chen et al. Neoplasia Vol. 16, No. 8, 2014injury markers at 9 months, a trend of mildly elevated ALT and ALP
was detected in cGrp94f/f mice at 15 months, and substantial increase
in ALT and ALP was observed at 21 months, concurrent with tumor
formation (Figure 1D). cGrp94f/f livers exhibited an about 1.6-fold
increase in apoptosis at 9 and 15 months, and a 2.7-fold increase at
21 months; however, the percentage of apoptotic cells remained
below 0.6% at 21 months (Figure 1E).
Progressive Repopulation of cGrp94 f/f Livers with
GRP94-Positive Hepatocytes
Recent studies revealed that in conditional knockout models of ER
chaperone in specific tissues, repopulation with non-recombined cells
expressing the chaperone protein could occur [23–25]. To test this, we
first examined the expression pattern of GRP94 in liver tissues from
WT and cGrp94f/f mice by immunohistochemistry (IHC) staining.
Our results showed that while GRP94 expression was largely ablated in
cGrp94f/f livers at 2 months of age, by 9 months patches of the liver
exhibited positive GRP94 staining which intensified progressively from
15 to 21 months, with most of the GRP94-positive cells being
hepatocytes (Figure 2A). Western blot of liver lysates isolated fromWT
and cGrp94f/f mice confirmed gradual repopulation of GRP94-positive
cells in cGrp94f/f livers as the mice aged, reaching about 40% of theWT
level at 15 months (Figure 2B). At 21 months, the level of GRP94 in
cGrp94f/f liver tumor lysates was further elevated at about 60% of the
WT level (Figure 2B).Figure 2. Progressive repopulation of GRP94-positive hepatocytes in c
ages. NT: non-tumor tissue. T: tumor tissue. Scale bar: 200 μm. (B) We
lysates from non-tumor tissues. T: liver lysates from tumor tissues. β-a
are shown on the bottom. Data are presented as mean ± s.e. (**P b 0Increased Proliferation Preceding Hepatocellular Carcinoma
Formation and Ductular Reactions in Livers of Aged
cGrp94 f/f Mice
Histological analysis of cGrp94f/f livers at 15 months showed mild
fat accumulation, and the small nodules in these livers exhibited a
combination of fat and hydropic change as evidenced by extensive
cellular swelling (Figure 3A). IHC staining revealed patchy GRP94
expression in cGrp94f/f livers with even higher level of repopulation of
GRP94-positive cells in the small nodules, correlating with increased
proliferation as revealed by Ki67 staining (Figure 3A). Double
staining of GRP94 and Ki67 confirmed that Ki67-positive cells were
GRP94-positive (Figure 3B).
At 21 months of age, a trabecular pattern of HCC was evident and
ductular reactions (DRs) were also detected in the tumor region of
cGrp94f/f livers (Figure 3C). DR is the expansion of activated biliary
epithelial cells in response to injury, and contains LPCs as well as a
complex of ECM, inflammatory cells, and mesenchymal cells [26,27].
Additionally, fibrosis was detected in the liver tumors in 50% of
cGrp94f/f mice (Figure 3C). IHC staining revealed GRP94 expression
and markedly higher Ki67 staining in cGrp94f/f livers (Figure 3C).
GRP94 and Ki67 double staining further showed that most
proliferating cells expressed GRP94 in cGrp94f/f livers (Figure 3D).
To characterize cGrp94f/f liver tumors, IHC staining of HepPar1,
panCK, and α-SMA was performed on consecutive liver slides. While
HepPar1 stained hepatocytes of WT livers at a low basal level, strongGrp94f/f livers. (A) GRP94 IHC in WT and cGrp94f/f livers at indicated
stern blot of liver lysates to detect GRP94 at indicated ages. NT: liver
ctin served as the loading control and corresponding quantifications
.01 and ***P b 0.001).
Figure 3. Increased proliferation and development of ductular reactions (DRs), fibrosis, and HCC in cGrp94f/f livers. (A) Liver H&E staining,
GRP94, and Ki67 IHC at 15 months. SN: small nodule. Scale bar: 100 μm. (B) Immunofluorescent staining with GRP94 (green) and K67
(red) at 15 months. White arrows denote double-positive cells. Nuclei were stained with DAPI (blue). Scale bar: 25 μm. (C) Same as A but
at 21 months. (D) Same as B but at 21 months.
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trabecular structures (Figure 4A). panCK staining marked bile ducts
in the WT and highlighted DR areas in cGrp94f/f livers (Figure 4A).
Interestingly, some HepPar1-labeled cells in HCC were also co-
stained by panCK, raising the possibilities that they might come from
the common progenitors, or hepatocytes might transdifferentiate into
bile duct cells in the aged liver undergoing tumorigenesis. In WT
livers, α-SMA stained smooth muscle cells in vessel walls. In contrast,
many α-SMA-positive stellate cells were detected in cGrp94f/f tumors
(Figure 4A) indicating stellate cell activation. Stellate cells represent
the major cell type for matrix production, resulting in liver fibrosis
[28] observed in cGrp94f/f livers at 21 months (Figure 3C).
Furthermore, the development of HCC in cGrp94f/f livers was
confirmed by strong CD34 staining, which showed endothelial cells
surrounding the trabeculae (Figure 4B). Staining of glutamine
synthetase (GS), a liver zonation marker expressed in about 50% of
HCC [29], was also performed. GS staining labeled central vein
(CV)-associated hepatocytes in the WT but revealed decreasedspacing between GS-positive regions in cGrp94f/f livers at both 15
and 21 months. Increased GS expression with an irregular
distribution was also observed in cGrp94f/f livers at 21 months,
consistent with HCC formation (Figure 4C).
Activation of Oncogenic Signaling in Premalignant
cGrp94 f/f Livers
To identify potential molecular mechanisms contributing to
tumorigenesis in aged cGrp94f/f mice, we examined key oncogenic
pathways implicated in HCC in premalignant livers at 15 months,
prior to the tumor onset. Our analysis showed prominent
upregulation of TGF-β1 (Figure 5A), one of the most potent
activators for stellate cell activation and liver fibrosis [28]. We also
observed elevated level of its downstream target p-SMAD3 and a mild
increase in p-SMAD2 (Figure 5A). This is in agreement with SMAD3
playing a more important role than SMAD2 in the development of
liver fibrosis [30]. Additionally, we observed elevation of p-ERK and
p-JNK, but not p-AKT in cGrp94f/f livers (Figure 5B). The
Figure 4. Characteristics of cGrp94f/f liver tumors. (A) H&E staining, HepPar1, panCK, and α-SMA IHC in WT livers and cGrp94f/f liver
tumors at 21 months. Scale bar: 100 μm. (B) H&E and CD34 IHC in WT livers and cGrp94f/f HCC at 21 months. Scale bar: 100 μm. (C) GS
IHC in livers at indicated ages. CV: central vein. Scale bar: 300 μm.
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increased (Figure 5B), consistent with higher proliferation of
cGrp94f/f livers prior to tumor development.
Since TGF-β is an inducer of epithelial-mesenchymal transition
(EMT), which may contribute to tumorigenesis [31], EMT markers
vimentin and E-cadherin were examined. We detected strong
upregulation of the epithelial marker E-cadherin; however, there was
no apparent difference in the levels of the mesenchymal marker
vimentin, which displayed similar variation (Figure 5C). TGF-β
signaling can also activate integrin β1 to induce EMT [32]. However,
similar integrin β1 expression levels were detected inWT and cGrp94f/f
livers (Figure 5C). Thus, despite increased TGF-β1 in premalignant
cGrp94f/f livers, EMT was not evident. Recently, it has been reported
that GRP94 is an essential chaperone of the Wnt co-receptor LRP6,
required for Wnt/β-catenin signaling [4]. Nevertheless, the levels of
both total and active β-catenin were similar in WT and cGrp94f/f
livers (Figure 5D).
Expansion of GRP94-Negative Liver Progenitor Cells and
Ductular Reactions in cGrp94 f/f Mice
We previously demonstrated that liver-specific deletion of Grp94
leads to LPC proliferation [7], and bi-potential LPCs could give rise
to liver tumors [12]. To address the origin of GRP94-positive HCCin cGrp94f/f mice, double staining of GRP94 and the LPC/bile duct
marker panCK was performed on liver sections at 21 months. panCK
labeled LPC/bile duct cells as well as DRs, and while WT bile duct
cells co-expressed GRP94 and panCK, most LPC/bile ducts in
cGrp94f/f livers were devoid of GRP94 expression (Figure 6A and B).
Moreover, in agreement with DRs in cGrp94f/f livers at 21 months,
we observed increased panCK-positive cells, many of which
migrated away from portal veins, suggesting expansion of LPCs
in cGrp94f/f livers (Figure 6A). LPC expansion was also detected in
cGrp94f/f livers from 2 to 15 months of age, while DRs were
observed at 15 months (Figure 6C). Quantitation of the stained cells
confirmed that in contrast to theWT, almost all panCK-positive cells
in cGrp94f/f livers were GRP94-negative (Figure 6D). Collectively,
these results showed expansion of GRP94-negative LPCs in
cGrp94f/f livers, giving rise to the GRP94-negative DRs in aged
cGrp94f/f mice. Since HCC was mostly GRP94-positive and LPCs
were mostly GRP94-negative, it is unlikely that HCC was
primarily derived from LPCs.
Discussion
Based on the recent discovery that Grp94 knockout in the liver and
bone marrow leads to progenitor/stem cell expansion [7,33,34], and
such cells can fuel tumorigenesis, here we investigate whether GRP94
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Figure 5. Activation of oncogenic signaling in premalignant cGrp94f/f livers at 15 months. (A) Representative Western blots of liver lysates
for TGF-β1 and SMAD2/3. (B) Representative Western blots for the indicated kinases and cyclin D1. (C) Representative Western blots for
vimentin, E-cadherin and integrin β1. (D) Representative Western blots for total and active β-catenin.
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formation. In this study, we provide the first demonstration that as
cGrp94f/fmice aged, abnormal small nodules surfaced at 15months and
aggressiveHCCwas evident by 21months, associating with liver injury,
LPC expansion and repopulation of GRP94-positive hepatocytes. As
summarized in Figure 7, we observed that at the early stage, GRP94
level was 10-30% of the WT and most hepatocytes and LPCs were
GRP94-negative. At 15 months, GRP94 expression reverted back to
40% of the WT level. HCC developed at 21 months was mostly
GRP94-positive, whereas most DRs remained GRP94-negative. This
implies that the tumor development in cGrp94f/f livers is not due to the
lack of GRP94 in tumor cells, but rather caused by some cell
autonomous and/or non-autonomous events at the premalignant stage
triggered by GRP94 deficiency.
Since GRP94 possesses anti-apoptosis properties [6,35] and is
required for the processing and secretion of IGF-1, which is protective
against liver injury [36,37], we measured liver injury and apoptosis. We
detected a limited elevation in ALT and ALP at 15 months prior to the
onset of tumorigenesis, and a general increase in apoptosis spanning
from 9 to 21 months. While these effects are modest, chronic exposure
to mild liver injury during the aging process, when other mutations
could accumulate, may trigger the adaptive response of expanding
LPCs, which was observed in cGrp94f/f mice.
In examining the alteration of signaling pathways in premalignant
cGrp94f/f livers, we observed concurrent increase in LPCs and
TGF-β1 level, associating with SMAD2/3 activation. While
activation of SMAD2/3 stimulates stellate cell activation and fibrosis
[30], establishing a tumor reactive stroma [38], TGF-β in the
microenvironment maintains TICs [31]. Furthermore, TGF-βexposure under chronic liver damage can induce transformation of
LPCs, giving rise to liver TICs [17]. Thus, it is possible that TGF-β1
contributes to the generation of DRs from transformed LPCs in
cGrp94f/f livers. Paradoxically, TGF-β is also anti-proliferative in
most epithelial cells, including hepatocytes, but cancer cells can
escape the tumor suppressor function of TGF-β [31]. Therefore,
GRP94-positive hepatocytes might develop mechanisms to become
resistant to TGF-β1-mediated growth inhibition. Concurrent gene
alterations can also influence whether TGF-β promotes or suppresses
tumor growth. For example, in the setting of p53 loss, TGF-β
signaling enhances liver tumorigenesis [39]. It will be interesting to
dissect the factors in aging cGrp94f/f mice that synergize with TGF-β
signaling in liver tumor development.
Both ERK and JNK activation have been reported in HCC [18,19].
JNK activity in HCC is significantly correlated with stem cell marker
CD133 expression [20]. Similarly, ERK pathway is associated with
aggressive tumor behaviors and promotes proliferation of Sca-1-positive
LPCs [18,21]. Although ERK activation was not detected in young
cGrp94f/f mice at 2 months, we also observed increased p-ERK in
cPtenf/fGrp94f/f livers, which formed mixed lineage tumors at 8–9
months [7]. Additionally, E-cadherin has been suggested as a tumor
suppressor in various cancers and E-cadherin overexpression inhibits
proliferation and invasiveness [40]. However, recent studies indicate
that its role might be more complex, such that loss or upregulation of
E-cadherin levels identify two distinct categories of HCC in both
humans and transgenic mice [41,42]. Overexpression of E-cadherin
has been linked to invasive potential of tumor cells, including HCC
[41,43–45]. Further studies are required to address the causative
roles of these pathways in GRP94-mediated liver tumors.
Figure 6. Expansion of GRP94-negative LPCs in cGrp94f/f livers. (A) Immunofluorescent staining of WT and cGrp94f/f livers at 21 months
with panCK (green) and GRP94 (red). Nuclei were stained with DAPI (blue). White arrows denote panCK-positive cells migrating away from
the portal vein (PV). Scale bars: 25 μm. (B) Magnified panCK-positive cells stained for GRP94 in WT and cGrp94f/f livers at 21 months.
White arrows indicate examples of panCK, GRP94 double-positive cells. Scale bar: 10 μm. (C) Immunofluorescent staining of panCK
(green) and GRP94 (red) in cGrp94f/f livers at 2, 9, and 15 months. Scale bar: 25 μm. (D) Quantitation of panCK, GRP94 double-positive
cells (***P b 0.001, χ2 test).
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mice raises the intriguing question on the cell origin of cGrp94f/f
tumors. We speculate that since cells in the small nodules at 15 months
were GRP94-positive hepatocytes with high proliferative activity, they
could gain growth advantage, giving rise to the GRP94-positive HCC
(Figure 7). Although LPCs also can contribute to HCC, due to GRP94
deletion inmost cGrp94f/f LPCs, they are more likely to be the origin of
GRP94-negative DRs in the liver tumors rather than the GRP94-
positive HCC. Nonetheless, given the recent report that hepatocytescan undergo cellular conversion to biliary epithelial cells following
injury [46], we cannot rule out that DRs might be derived from a
subfraction of hepatocytes that are GRP94-negative. Likewise, a small
fraction of GRP94-positive LPCs, which escape Cre at an earlier stage,
might generate HCC. Future studies using specific cell lineage markers
will be required to resolve this and our cGrp94f/f model may offer such
an opportunity.
Lastly, in agreement with GRP94 expression in cGrp94f/f HCC
cells, progressive repopulation of GRP94-positive cells was also
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Figure 7. Schematic model of GRP94 expression pattern and liver tumor development in cGrp94f/f mice. The major phenotypes at each
stage are listed below.
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unpublished results). GRP94 is upregulated in HBV-induced human
HCC correlating with its progression [47,48], and in Pten-null
mediated mouse liver cancer (data not shown). Nonetheless,
conditional knockout of GRP94 in the liver resulted in HCC in
aged mice. How can these observations be reconciled? We
hypothesize that in specific organs, such as the liver, where loss of
GRP94 leads to LPC activation, tumorigenesis could occur in
combination with other carcinogenic events activated during the
aging process. Furthermore, there is generally a gain of GRP function
in cancers in response to stress associated with tumorigenesis [2], and
the anti-apoptotic function of GRP94 could confer survival advantage
to cancer cells. Interestingly, GRP94-specific inhibitors have been
identified [49,50], and one of them reduces viability of HER2-
overexpressing breast cancer cells and multiple myeloma cells in vitro
[8,49]. Given that hepatic GRP94 deficiency for 9 months in the
mice leads to only minor liver injury and apoptosis, short-term
treatment of cancers with these inhibitors might have minimal
harmful effects on normal livers while reducing GRP94 activity
in HCC.
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